ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial / / Lancet. 2003. Vol. 361. P.1149-1158.
15. Sever P., Dahlof B., Wedel H. et al. Potential synergy between lipid-lowering and blood-pressure-lowering In the Anglo-Scandinavian Cardiac Outcomes Trial / / Eur. Heart J. 2006. Vol. 27. P. 2982-2988.
16. Heart Protection Study Collaborative Group. MRC / BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk patients: a randomized placebo-controlled trial / / Lancet. 2002. Vol 360. P. 7-22.
17. Shepherd J., Blauw GJ, Murphy MB, Bollen E. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial / / Lancet. 2002. Vol. 360. P. 1623-1630.
18. Jones P.H., Davidson M.H., Stein E.A. et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial) / / Am. J. Cardiol. 2003. Vol. 92. P.152-160.
19. Kjekshus J., Pedersen T.R., Olsson A.G. et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease / / Am. Heart J. 2002. Vol. 144. P.1044-1051.
20. Schuster H., Fox J.C. Investigating cardiovascular risk reduction - the Rosuvastatin GALAXY Programme / / Exp. Opin. Pharmacother. 2004. Vol. 5 (5). P. 1187-1200.
21. Biasetto J.W., Stein E.A., Brown W.V. et al. Efficacy of rosuvastatin compared with other statins at seleted starting doses in hypercholesterolemic patients and special population groups / / Am. J. Cardiol. 2003. Vol. 91 (Suppl). P. 3-10.
22. Hunningbake D.B., Stein E.A., Bays H.E. et al. Rosuvastatin improves the atherogenic and atheroprotective lipid profile in patients with hypertriglyceridemia / / Coron. Artery Dis. 2004. Vol. 15. P. 115-123.
23. Nishiwaki M., Ikewaki K., Avaori M. et al. Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: A post hoc analysis of MEGA Study / / J. Cardiol. 2012. Dec. 19, pii: S0914-5087 (12) 00283-3.
24. Hyng C.Y., Lin C.H., Loh el-W. et al. Ting CT, Wu TJ CHADS (2) Score, Statin Therapy, and Risk of arterial Fibrillation / / Am. J. Med. 2013. Vol. 126 (2). P.133-140.
25. Kosoglou T., Meyer I., Musiol B. et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin / / Atherocslerosis. 2000. Vol. 151. P. 135.
26. Farnier M., Averna M., Missault L. et al. Lipid-altering efficacy of ezetimibe / simvastatin 10/20mg compared with rosuvaststin 10-mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study / / Int. J. Clin. Pract. 2009. Vol 63 (4). P. 547-559.
27. Nissen S., Nichols S., Sipahi L. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial / / JAMA. 2006. Vol. 295 (13). P. 1556-1565.
28. Crouse III J.R., Raichlen J.S., Riley W.A. et al. Effect of Rosuvastatin on Progression of Carotid IntimaMedia Thickness in ...
